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Abstract
Enterovirus-positive samples diagnosed in Marseille (January
2009 to September 2011) were screened for EV71 by real-time
RT-PCR. EV71 was detected in three children below the age of
2 years with no history of overseas travel; two of these cases
were associated with severe clinical presentation. Viruses dem-
onstrated genetic similarity to other European genogroup C2
strains. Strain MRS/09/3663 complete sequencing revealed 97.6%
identity across the entire genome with a 2008 Singapore isolate,
without signs of possible recombination events. To our knowl-
edge, this is the first detection of EV71 infection in Marseille,
France, that confirms the current circulation of EV71 in France.
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Enterovirus 71 (EV71, family Picornaviridae, species Human
Enterovirus A, classified into genogroups based on VP1 capsid
sequence) is a frequent aetiological agent of hand, foot and
mouth disease (HFMD). EV71 can cause neurological compli-
cations, especially in children under 5 years old, and is the
most common non-polio enterovirus associated with polio-
myelitis-like paralysis [1]. EV71 has emerged as a significant
public health threat, with major epidemics reported in the
Asia-Pacific region over the last two decades but none in
Europe. The possibility of genetic variants provoking epidem-
ics in Europe underlies the continuous enterovirus surveil-
lance. In this context, we describe the molecular screening
for EV71 in EV-positive samples between 2009 and 2011 in
the Public Hospitals of Marseille, France, and the molecular
characterization of detected strains.
A total of 8041 samples registered in the Microbiology
Department between January 2009 and September 2011
were processed as illustrated (Fig. 1a). Cerebrospinal fluids
(CSF, 70.9% of samples) were tested for EV RNA with the
Xpert EV kit (GeneXpert, Cepheid, Sunnyvale, CA, USA)
and confirmed using the routine pan-enterovirus real-time
RT-PCR test [2,3]. Other sample types (e.g. stool or pharyn-
geal swabs) were directly tested with the routine diagnostic
assay. Of 682 (8.5%) samples that tested EV-positive: 77.5%
were sampled during the seasonal peaks of EV incidence
(May–August); the male-to-female ratio was 1.73:1; and 70%
were obtained from patients below 10 years old (24%
<1 years old, 46% 1–9 years old).
Prospective EV71 screening was conducted over two peri-
ods of peak EV activity (May–October 2010, May–September
2011): if a patient had multiple EV-positive samples, only one
was subsequently tested. A total of 174 EV-positive samples
from 174 patients were tested prospectively by a EV71-spe-
cific real-time RT-PCR assay adapted from Tan et al., with a
modified hybridization probe (Fig. 1b) and a specific external
control [4,5]. Two samples tested EV71-positive (June 2010;
April 2011). Retrospective screening was carried out on
archived EV-positive samples from 2009 to May 2010 that
were available for analysis: 182 samples were tested retro-
spectively, yielding one EV71-positive sample (June 2009).
Serotype was determined for regular surveillance purposes,
and VP1 analysis confirms the occurrence of three EV71
infections during the study period.
Case MRS/09/3663 was a 22-month-old female patient
(10 kg) hospitalized in June 2009. She was febrile and expe-
rienced loss of consciousness (c. 2 min), ocular revulsion,
eye deviation to the right, and generalized tonic-clonic sei-
zure (c. 15 s). The post-critical phase included stiffness,
hyperextension of the left arm and persisting ocular revul-
sion. She was intubated and extubated after 12 h. CSF
white blood count (WBC) was 7/mm3 and RBC count was
20/mm3. EV71 was detected in a pharyngeal swab. The
patient was discharged 3 days after admission and showed
no sequelae.
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Case MRS/10/8229 was a 1-month-old female patient
(4.7 kg) admitted in June 2010 with fever and appetite loss,
without neck stiffness. CSF analysis revealed hyper-
proteinorrhachia (1.07 g/L), glycorrhachia (2.9 g/L), WBC
count 6/mm3 and RBC count 2400/mm3. EV71 was detected
in a stool. The patient was discharged 3 days after admission
and showed no sequelae.
Case MRS/11/8134 was a 3-month-old female patient
admitted in April 2011 with persistent fever, diarrhoea,
altered neurological status, convergent strabismus and left
eyelid ptosis. She was intubated and extubated 2 days later.
CSF analysis revealed hyperproteinorrhachia, WBC count
was 8/mm3 and RBC count 2000/mm3. EV71 was detected in
a pharyngeal swab. The patient was discharged 4 days after
admission and showed no sequelae.
Two EV71-positive samples were isolated in BGM cells
(strains MRS/09/3663 and MRS/11/8134), and their VP1 com-
pletely amplified for genogroup identification (891 nt). Sam-
ple MRS/10/8229 was partially amplified (354 nt) directly
from CSF [6]. Phylogenetic analysis showed that MRS/09/
3663, MRS/10/8229 and MRS/11/8134 clustered with the C2
subgenogroup (bootstrap 91%, Fig. 2a). Analysis comprised
all C2 VP1 sequences available in GenBank (n = 281, as of 22
April 2011), including strains isolated in Australia (1995–
1999), the USA (1995–1997), Japan (1997–2004, 2009–2010),
the Netherlands (1997–2010), Taiwan (1998, 2008), Great
Britain (1999–2010), France (2000–2009) and Germany
(2006–2007). MRS/09/3663 and MRS/11/8134 shared 90.2–
98.7% identity with C2 strains, amongst which European
strains from 2006 to 2008 were the most genetically similar.
The closest non-European strains were from Japan (2009–
2010) and Singapore (2008). Notably, a fatal EV71 strain
reported in Brest, France (2007), shared 97.9–98.2% identity
with the Marseille strains.
Strain MRS/09/3663 was completely amplified (Table S1),
gel-purified and sequenced (accession number JN835312). Phy-
logenetic analysis of the complete nucleotide sequence (7395
nt) with all complete genome sequences available in GenBank
(n = 108, as of 22 April 2011) showed that MRS/09/3663
grouped with a 2008 strain isolated in Singapore (bootstrap
FIG. 1. Specimen processing and EV71 detec-
tion. (a) Flowchart for clinical specimen pro-
cessing. CSF, cerebrospinal fluid; BGM, Buffalo
Green Monkey renal cells; MRC5, human foe-
tal lung fibroblasts; IFA, immunofluorescence
assay. (b) Nucleotide sequences of the hybrid-
ization probes for the specific amplification of
EV71. The positions of all probes are those
relative to EV71 prototype strain BrCr (acces-
sion No. U22521). As described in Tan et al.
[5].
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FIG. 2. Phylogenetic and genetic analyses of the detected EV71 strains with all complete genome and genogroup C2 VP1 sequences available in
GenBank. Aligned nucleotide sequences were analysed phylogenetically in MEGA v3.1 (neighbour-joining method, Jukes-Cantor model, 1000
pseudoreplicates). CVA16-G-10 (accession No. U05876) was added as an outlier for both trees. (a) In the VP1 coding region, MRS/09/3663,
MRS/11/8134 (both 891 nt) and MRS/10/8229 (354 nt) clustered reliably (bootstrap 91%) with sequences of the C2 subgenogroup, which
included FJ824734, a fatal strain isolated in France in 2007. (b) Full-length MRS/09/3663 grouped reliably (bootstrap 100%) with FJ172159, iso-
lated in 2008 in Singapore. (c) MRS/09/3663 was used as the query sequence with a 500-nt sliding window and steps of 20 nt (neighbour-joining
method, Kimura 2-parameter model, 100 pseudoreplicates) in SimPlot v3.5.1. Signals between 75% and 100% were observed across the entire
genome with FJ172159 exclusively. No other evidence of possible recombination events was observed.
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100%, 97.6% identity) (Fig. 2b). Bootscanning analysis indicated
that similarity to this strain is consistent across the entire gen-
ome, without evidence for recombination events.
In Marseille, a study of EV isolates did not identify EV71
between 1985 and 2005 [7]. Studies of sporadic cases in Eur-
ope identified mostly viruses from subgenogroup C1 from
1998 to 2006, and C2 viruses since 2006 [8]. The latter have
been linked to severe neurological disease during the 1998
outbreaks in Taiwan and Australia [9]. However, the VP1
A170V substitution suggested to be associated with increased
neurovirulence was absent in the Marseille strains, in the fatal
Brest strain, and in other available European C2 strains. There
is no firm evidence that virulence is associated with genogroup
or with this specific substitution. C4 genogroup viruses, which
have been increasingly identified in the Asia-Pacific region and
associated with lethal infection and adult-onset encephalitis,
are less frequent in Europe: in 2004, two cases were isolated
in Austria, one in France and one in Germany [10–14].
The current study reports the first detection of EV71 infec-
tion in Marseille, southern France. The patients had no history
of travel prior to disease onset, confirming that C2 genogroup
viruses circulate in France and are, based on phylogenetic
analyses with exhaustive sequence data, likely to have been
introduced from the Asia-Pacific region. In contrast to EV71
strains isolated in Asia, no evidence for recombination was
identified following complete genome characterization [15].
Case reports indicate that EV71 currently circulating in Eur-
ope has the potential to cause severe presentations with neu-
rological complications. A close epidemiological monitoring of
EV71 infections and genogroup patterns is recommended, as
well as further evaluation of sensitivity and genogroup cover-
age of this EV71-specific assay.
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